Quick Takeaways
- CLNN - Clene Inc. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: -$5,591,940.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 17 Insiders of Clene Inc.
- Symbol
- CLNN on Nasdaq
- Location
- Salt Lake City, UT
What Changed
- Buy value: $216,664; sell value: $5,808,604.
- Net share flow: -944,750.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$5,591,940.
Buys
$216,664
Shares: 33,333
Insiders: 1
Sells
$5,808,605
Shares: 978,083
Insiders: 2
Net
-$5,591,940
Shares: -944,750
Insiders: -1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 446,583 | $0 | $2,636,999 | -$2,636,999 |
| 3-6 | 33,333 | 525,239 | $216,664 | $3,144,162 | -$2,927,498 |
| 6-9 | 0 | 3,401 | $0 | $18,161 | -$18,161 |
| 9-12 | 0 | 2,860 | $0 | $9,283 | -$9,283 |
Clene Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| General Resonance LLC | 10%+ Owner | $3,762,515 | -$27,444 | -0.72% | Filing P/S | 21 Aug 2025 |
| David J. Matlin | Director | $3,105,856 | +$216,665 | +7.5% | Filing P/S | 19 Feb 2026 |
| Alison Mosca | Director | $3,005,527 | Mixed | 19 Feb 2026 | ||
| Chidozie Ugwumba | 10%+ Owner | $641,185 | -$5,781,161 | -90% | Filing P/S | 01 May 2026 |
| Morgan R. Brown | Chief Financial Officer | $53,800 | Mixed | 22 Jan 2026 | ||
| Robert Glanzman | Chief Medical Officer | $4,331 | Mixed | 16 May 2022 | ||
| Shalom Jacobovitz | Director | Mixed | 19 Feb 2026 | |||
| Matthew Kiernan | Director | Mixed | 19 Feb 2026 | |||
| Arjun Jj Desai | Director | Mixed | 19 Feb 2026 | |||
| Reed N. Wilcox | Director | Mixed | 19 Feb 2026 | |||
| Mark Mortenson | Chief Science Officer | Mixed | 22 Jan 2026 | |||
| Robert Dee Etherington | President & CEO, Director | Mixed | 22 Jan 2026 | |||
| Fiona Costello | Director | Mixed | 18 May 2021 | |||
| Jonathon Gay | Director | Mixed | 19 Feb 2026 | |||
| Tae Heum Jeong | Chief Finance Officer | Mixed | 04 Nov 2021 | |||
| Vallerie McLaughlin | Director | Mixed | 19 Feb 2026 | |||
| John Henry Stevens | Director | Mixed | 18 Sep 2023 |
Top shareholders of Clene Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Chidozie Ugwumba |
13D/G
3/4/5
|
Ugwumba Chidozie · 10%+ Owner |
9.7%
|
1,351,071
|
$7,782,169 | -$3,251,975 | 11 May 2026 | |
| General Resonance LLC |
3/4/5
|
10%+ Owner |
5.1%
|
704,591
|
$3,762,515 | -$27,444 | 21 Aug 2025 | |
| David J. Matlin |
3/4/5
|
Director |
—
mixed-class rows
|
578,029
mixed-class rows
|
$3,105,856 | +$216,665 | 19 Feb 2026 | |
| AWM Investment Company, Inc. |
13D/G
|
— |
4.7%
|
500,000
|
$3,012,500 | $0 | 30 Sep 2025 | |
| Alison Mosca |
3/4/5
13D/G
|
Director |
13%
from 13D/G
|
709,655
mixed-class rows
|
$3,005,527 | — | 19 Feb 2026 | |
| Boxer Capital Management, LLC |
13F
|
Company |
3.4%
|
477,515
|
$2,354,149 | — | 31 Mar 2026 | |
| SymBiosis Capital Partners, LLC |
13F
|
Company |
3.1%
|
431,094
|
$2,125,293 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.2%
|
308,230
|
$1,519,574 | — | 31 Mar 2026 | |
| SCOGGIN MANAGEMENT LP |
13F
|
Company |
2.2%
|
300,000
|
$1,479,000 | — | 31 Mar 2026 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
1.9%
|
257,872
|
$1,271,309 | — | 31 Mar 2026 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
419,101
|
$1,257,303 | $0 | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.69%
|
95,874
|
$473,042 | — | 31 Mar 2026 | |
| Lunt Capital Management, Inc. |
13F
|
Company |
0.38%
|
52,260
|
$257,642 | — | 31 Mar 2026 | |
| PEAK6 LLC |
13F
|
Company |
0.36%
|
50,012
|
$246,559 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.31%
|
43,715
|
$215,515 | — | 31 Mar 2026 | |
| PARSONS CAPITAL MANAGEMENT INC/RI |
13F
|
Company |
0.27%
|
37,243
|
$183,608 | — | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
|
Company |
0.24%
|
33,799
|
$166,629 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
0.21%
|
29,801
|
$146,919 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.14%
|
19,832
|
$97,772 | — | 31 Mar 2026 | |
| 4LIFE RESEARCH LLC |
13D/G
|
David Lisonbee |
6.5%
|
555,328
|
$84,921 | $0 | 20 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.12%
|
16,143
|
$79,585 | — | 31 Mar 2026 | |
| PENN DAVIS MCFARLAND INC |
13F
|
Company |
0.08%
|
11,000
|
$54,230 | — | 31 Mar 2026 | |
| Morgan R. Brown |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
55,000
mixed-class rows
|
$53,800 | — | 22 Jan 2026 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.04%
|
5,927
|
$29,220 | — | 31 Mar 2026 | |
| Vanguard Global Advisers, LLC |
13F
|
Company |
0.04%
|
5,609
|
$27,652 | — | 31 Mar 2026 | |
| JONES FINANCIAL COMPANIES LLLP |
13F
|
Company |
0.04%
|
5,000
|
$23,550 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
3,977
|
$19,607 | — | 31 Mar 2026 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0.02%
|
2,735
|
$13,484 | — | 31 Mar 2026 | |
| Atlantic Private Wealth, LLC |
13F
|
Company |
0.02%
|
2,205
|
$10,871 | — | 31 Mar 2026 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.01%
|
1,926
|
$9,495 | — | 31 Mar 2026 | |
| Robert Glanzman |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
10,564
|
$4,331 | — | 16 May 2022 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
686
|
$3,382 | — | 31 Mar 2026 | |
| Arax Advisory Partners |
13F
|
Company |
0%
|
570
|
$2,811 | — | 31 Mar 2026 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
444
|
$2,189 | — | 31 Mar 2026 | |
| MAI Capital Management |
13F
|
Company |
0%
|
100
|
$493 | — | 31 Mar 2026 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
25
|
$123 | — | 31 Mar 2026 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
23
|
$113 | — | 31 Mar 2026 | |
| US BANCORP \DE\ |
13F
|
Company |
0%
|
20
|
$99 | — | 31 Mar 2026 | |
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
— |
10%
|
1,886,469
|
— | $0 | 31 Mar 2026 | |
| Robert Dee Etherington |
3/4/5
|
President & CEO, Director |
—
mixed-class rows
|
120,000
mixed-class rows
|
— | — | 22 Jan 2026 | |
| Mark Mortenson |
3/4/5
|
Chief Science Officer |
—
mixed-class rows
|
115,000
mixed-class rows
|
— | — | 22 Jan 2026 | |
| Tae Heum Jeong |
3/4/5
|
Chief Finance Officer |
—
class O/S missing
|
62,500
|
— | — | 04 Nov 2021 | |
| Fiona Costello |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
— | — | 18 May 2021 | |
| John Henry Stevens |
3/4/5
|
Director |
—
class O/S missing
|
27,517
|
— | — | 18 Sep 2023 | |
| Jonathon Gay |
3/4/5
|
Director |
—
mixed-class rows
|
10,012
mixed-class rows
|
— | — | 19 Feb 2026 | |
| Arjun Jj Desai |
3/4/5
|
Director |
—
mixed-class rows
|
9,189
mixed-class rows
|
— | — | 19 Feb 2026 | |
| Vallerie McLaughlin |
3/4/5
|
Director |
—
mixed-class rows
|
8,789
mixed-class rows
|
— | — | 19 Feb 2026 | |
| Reed N. Wilcox |
3/4/5
|
Director |
—
mixed-class rows
|
8,542
mixed-class rows
|
— | — | 19 Feb 2026 | |
| Matthew Kiernan |
3/4/5
|
Director |
—
mixed-class rows
|
7,991
mixed-class rows
|
— | — | 19 Feb 2026 | |
| Shalom Jacobovitz |
3/4/5
|
Director |
—
mixed-class rows
|
5,598
mixed-class rows
|
— | — | 19 Feb 2026 |
Recent Insider Transactions by Companies or Individuals for Clene Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -41.5% | $454,435 | $6.20 | -73,296 | 103,417 | 12 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -11.2% | $149,695 | $6.75 | -22,177 | 176,713 | 11 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -26.8% | $495,611 | $6.80 | -72,884 | 198,890 | 04 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.09% | $34,828 | $6.01 | -5,795 | 271,774 | 01 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.02% | $34,875 | $6.08 | -5,736 | 277,569 | 30 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -4.12% | $68,517 | $5.63 | -12,170 | 283,305 | 29 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.54% | $9,387 | $5.90 | -1,591 | 295,475 | 28 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -17.1% | $376,658 | $6.14 | -61,345 | 297,066 | 21 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.19% | $26,426 | $6.12 | -4,318 | 358,411 | 20 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -6.46% | $161,007 | $6.43 | -25,040 | 362,729 | 17 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.96% | $49,587 | $6.40 | -7,748 | 387,769 | 16 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.59% | $41,304 | $6.48 | -6,374 | 395,517 | 15 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -5.84% | $119,889 | $4.81 | -24,925 | 401,891 | 02 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.99% | $21,262 | $4.97 | -4,278 | 426,816 | 01 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -13.6% | $331,796 | $4.88 | -67,991 | 431,094 | 31 Mar 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -3.02% | $79,234 | $5.10 | -15,536 | 499,085 | 30 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -3.28% | $82,982 | $4.75 | -17,470 | 514,621 | 27 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.99% | $28,723 | $5.40 | -5,319 | 532,091 | 26 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.3% | $39,039 | $5.50 | -7,098 | 537,410 | 25 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1% | $31,744 | $5.78 | -5,492 | 544,508 | 24 Mar 2026 | By SymBiosis II, LLC |
| Vallerie McLaughlin | CLNN | stock option | Award | 3,030 | 3,030 | 19 Feb 2026 | Direct | |||
| Reed N. Wilcox | CLNN | stock option | Award | 3,306 | 3,306 | 19 Feb 2026 | Direct | |||
| Alison Mosca | CLNN | stock option | Award | 4,201 | 4,201 | 19 Feb 2026 | Direct | |||
| David J. Matlin | CLNN | stock option | Award | 5,372 | 5,372 | 19 Feb 2026 | Direct | |||
| Arjun Jj Desai | CLNN | stock option | Award | 3,168 | 3,168 | 19 Feb 2026 | Direct | |||
| Shalom Jacobovitz | CLNN | stock option | Award | 4,098 | 4,098 | 19 Feb 2026 | Direct | |||
| Jonathon Gay | CLNN | stock option | Award | 3,271 | 3,271 | 19 Feb 2026 | Direct | |||
| Matthew Kiernan | CLNN | stock option | Award | 2,755 | 2,755 | 19 Feb 2026 | Direct | |||
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1% | $22,792 | $4.10 | -5,559 | 550,000 | 03 Feb 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.68% | $15,352 | $4.04 | -3,800 | 555,559 | 02 Feb 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.01% | $23,483 | $4.13 | -5,686 | 559,359 | 30 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.63% | $66,027 | $4.32 | -15,284 | 565,045 | 29 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.48% | $42,800 | $4.91 | -8,717 | 580,329 | 28 Jan 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.7% | $21,026 | $5.08 | -4,139 | 589,046 | 27 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.07% | $32,218 | $5.02 | -6,418 | 593,185 | 26 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.92% | $29,280 | $5.27 | -5,556 | 599,603 | 23 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.05% | $67,378 | $5.32 | -12,665 | 605,159 | 22 Jan 2026 | By Symbiosis II, LLC |
| Mark Mortenson | CLNN | stock option | Award | 75,000 | 75,000 | 22 Jan 2026 | Direct | |||
| Robert Dee Etherington | CLNN | stock option | Award | 75,000 | 75,000 | 22 Jan 2026 | Direct | |||
| Morgan R. Brown | CLNN | stock option | Award | 35,000 | 35,000 | 22 Jan 2026 | Direct | |||
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.92% | $61,201 | $5.05 | -12,119 | 617,824 | 21 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.94% | $59,674 | $4.80 | -12,432 | 629,943 | 20 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.22% | $40,645 | $5.13 | -7,923 | 642,375 | 16 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.9% | $64,071 | $5.10 | -12,563 | 650,298 | 15 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.87% | $100,460 | $5.12 | -19,621 | 662,861 | 14 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -3.68% | $127,653 | $4.89 | -26,105 | 682,482 | 13 Jan 2026 | By Symbiosis II, LLC |
| Alison Mosca | CLNN | Common Stock | Award | 6.32% | 16,667 | 280,500 | 13 Jan 2026 | By LLC | ||
| Alison Mosca | CLNN | Series B Warrants (Right to buy) | Award | 46,667 | 46,667 | 13 Jan 2026 | By LLC | |||
| Alison Mosca | CLNN | Series A Warrants (Right to buy) | Award | 20,000 | 20,000 | 13 Jan 2026 | By LLC | |||
| David J. Matlin | CLNN | common stock | Purchase | 7.5% | $216,664 | $6.50 | 33,333 | 477,824 | 13 Jan 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.